Search clinical trials for: BIA 9-1067

Total 3563 results

Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

Parkinson
Bial - Portela C S.A.

Completed

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Parkinson Disease

United Kingdom
Galderma R&D

Completed

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Bial - Portela C S.A.

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Parkinson Disease

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites

Parkinson Disease

Switzerland
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Parkinson's Disease

France, Russian Federation
Bial - Portela C S.A.

Completed

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Parkinson's Disease (PD)

Netherlands
Bial - Portela C S.A.

Completed

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

Epilepsy
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Galderma R&D

Completed

Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (COMET2)

Actinic Keratoses

Spain, France, Germany, Netherlands, Sweden
Bial - Portela C S.A.

Active, not recruiting

OpicApone Sleep dISorder (OASIS)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

Parkinson

Canada
Bial - Portela C S.A.

Recruiting

OpiCapone Effect on Motor Fluctuations and pAiN (OCEAN)

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Parkinson's Disease
Chang Gung Memorial Hospital

Completed

Application of Serial Body Composition Change for Risk Prediction in Treating Patients With Severe Pneumonia

Pneumonia

Taiwan
Universitair Ziekenhuis Brussel
Baxter Healthcare Corporation

Recruiting

Intra Dialytic Parenteral Nutrition and Nutritional Gap Nutritional Gap Identified by Indirect Calorimetry (DiaPaNIC)

Chronic Kidney Diseases | Protein Energy Wasting

Belgium
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
Bial - Portela C S.A.

Completed

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers

Parkinson's Disease
University of Copenhagen
Zealand University Hospital

Completed

The Relationship Between Fat Free Mass and Toxicity of Cytostatics in Cancer Patients

Colorectal Cancer | Pancreas Cancer

Denmark
Manchester University NHS Foundation Trust

Completed

Personality Traits in Patients Seeking a Consultation for Treatment for Floaters

Myodesopia

United Kingdom
University Hospital, Ghent

Completed

Watershift - Pilot Study (WATERSHIFT)

Nocturnal Polyuria | Total Body Water

Belgium
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. (BIPARKII)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Neurocrine Biosciences

Completed

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

Parkinson Disease

United States
Bial - Portela C S.A.

Completed

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Parkinson's Disease

Romania, Ukraine
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Opicapone in Clinical Practice (OPTIPARK)

Parkinson's Disease With Wearing-off Motor Fluctuations

Germany
AtheroGenics

Unknown

ARISE - Aggressive Reduction of Inflammation Stops Events

Myocardial Infarction | Coronary Artery Disease | Atherosclerosis | Unstable Angina

Canada, United States, United Kingdom, South Africa
Bial - Portela C S.A.

Completed

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Parkinson's Disease

Portugal, Romania, Ukraine
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Parkinson Disease

Canada
Miulli General Hospital

Unknown

Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test

Uremia

Italy
Taiwan Sunpan Biotechnology Development Co., Ltd.
Virginia Contract Research Organization Co., Ltd.

Completed

To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC. (TSB-9-W1)

Metastatic Colorectal Cancer

Taiwan

3

Subscribe